Summit is a clinical-stage oncology company trying to turn ivonescimab, a PD-1/VEGF bispecific, into a global lung-cancer platform. HARMONi-7 remains a recruiting global Phase III study, while the company’s first U.S. regulatory test is the HARMONi-based BLA, with an FDA action date of November 14, 2026.
The China trial cleared a meaningful efficacy bar. In 398 patients followed for 36 months, ivonescimab extended median overall survival to 30.8 months from 22.6 months with pembrolizumab, an 8.2-month gain and a 27% reduction in the risk of death. The interim OS result was statistically significant at HR 0.73 with p=0.009 (HARMONi-2 ITT). 〔0〕
| Measure | Ivonescimab | Pembrolizumab | Comparison |
|---|---|---|---|
| Median overall survival | 30.8 months | 22.6 months | +8.2 months |
| Overall-survival hazard ratio | — | — | 0.73; 95% CI 0.57–0.95; p=0.009 |
| PD-L1-high subgroup HR | — | — | 0.58; 95% CI 0.38–0.89 |
| Serious treatment-related adverse events | 29.9% | 21.6% | Higher with ivonescimab |
| Treatment-related discontinuations | 4.1% | 5.0% | Slightly lower with ivonescimab |
The result matters most because it strengthens the exact setting Summit is pursuing globally. HARMONi-2 tested monotherapy against pembrolizumab in PD-L1-positive NSCLC, while HARMONi-7 is testing the same basic comparison in a global population with PD-L1 expression above 50%. The especially strong PD-L1-high subgroup HR of 0.58 gives HARMONi-7 a more supportive precedent, although the subgroup analysis was descriptive and not formally powered (HARMONi-2 subgroup analyses).
The readout is validation, not a new commercial approval. Akeso already received Chinese authorization based on HARMONi-2, and Summit had already disclosed the positive OS direction before this filing; the new value is the mature survival detail and subgroup depth. Ivonescimab remains investigational in Summit’s license territories, including the United States and Europe, so this does not by itself establish regulatory success there. 〔1〕
The safety profile is manageable but not cleaner across every measure. The filing says there were no new safety signals with longer follow-up, and discontinuations were not higher, but serious treatment-related adverse events occurred more often with ivonescimab than with pembrolizumab. 〔2〕
Bottom line: This is a genuinely strong efficacy confirmation for ivonescimab and raises the evidentiary support for HARMONi-7. It is still China-only partner data, so the central business question—whether the benefit translates into global populations and Summit’s U.S. market—remains open.
Read the original 8-K on SEC EDGAR ↗